# The Role of Follistatin-like 1 in the Cross-Talk Among Osteoclastogenesis, Bone Marrow Stromal Cell Migration, and Osteoblastogenesis In Vitro

## TL;DR

This study shows that FSTL1, a protein from osteoclasts, helps control bone remodeling by reducing osteoclast activity and promoting bone-forming cell functions in lab experiments.

## Contribution

The study reveals FSTL1's novel role in enhancing osteoblast differentiation and migration while inhibiting osteoclast activity in vitro.

## Key findings

- FSTL1 suppresses osteoclast differentiation and resorption by reducing key markers like NFATc1 and TRAP.
- FSTL1 enhances mesenchymal stem cell migration and promotes osteoblast differentiation and mineralization.
- FSTL1 increases osteogenic markers such as Runx2 and osteocalcin in pre-osteoblasts.

## Abstract

Background: Bone remodeling depends on the dynamic balance between osteoclast-mediated bone resorption and osteoblast-mediated bone formation. Follistatin-like 1 (FSTL1) has been reported as an osteoclast-secreted protein that inhibits osteoclast differentiation, but its direct effects on osteoblast differentiation remain unclear. This study aimed to determine whether FSTL1 regulates osteoblast differentiation and mesenchymal stem cell migration and characterizes its role in osteoclast-osteoblast cellular cross-talk under in vitro conditions. Methods: Bone marrow-derived macrophages (BMMs) and stromal cells (BMSCs) from mice were used to induce osteoclast and osteoblast differentiation, respectively. Chemotaxis was assessed by Transwell migration, and osteoblast differentiation was evaluated in BMSC and MC3T3-E1 cells using staining, qRT-PCR, Western blotting, and proliferation assays. Results: FSTL1 significantly suppressed osteoclast differentiation and resorptive activity, confirmed by TRAP staining and pit assay, respectively. Expression of osteoclast markers such as NFATc1, TRAP, and DC-STAMP was reduced under FSTL1 treatment. In BMSCs, FSTL1 did not affect proliferation but significantly enhanced chemotaxis. Moreover, FSTL1 promoted osteogenic differentiation and mineralization, as demonstrated by increased ALP activity and Alizarin Red S staining. In MC3T3-E1 pre-osteoblasts, FSTL1 increased cell proliferation and mineralization by MTS and Alizarin Red staining. Key osteogenic markers, including Runx2 and osteocalcin, were also upregulated. Conclusions: Osteoclast-derived FSTL1 significantly suppresses osteoclastogenesis and promotes mesenchymal cell chemotaxis and osteogenic differentiation, indicating a role in regulating osteoclast–osteoblast cellular interactions in vitro. Targeting FSTL1 signaling may represent a promising therapeutic strategy for osteoporosis and other disorders of impaired bone remodeling.